

CHALLENGES IN GPCR DRUG DISCOVERY

G protein-coupled receptors (GPCRs) are the largest protein family encoded by the human genome and one of the key targets for therapeutic approaches across many disease areas. However, only around 25% of the druggable GPCRs have been tapped into. This presents a significant opportunity to develop novel medicines with high therapeutic impact for the GPCR class in numerous indications.

The Challenges in GPCR drug discovery workshop is co-organized by InSingulo and AstraZeneca and will explore the latest advancements in GPCR drug discovery research. Our aim is to bring together renowned international experts from industry, academia and service providers to facilitate communication between scientific groups and research areas within GPCR drug discovery community. Particular focus will be on topics such as computational approaches, biophysical studies, hit finding, structural biology and structure- and function-based drug discovery. We believe this will eventually lead to uncovering common challenges and finding new innovative approaches to drug discovery for GPCRs.

Confirmed Speakers


Stefan Geschwindner, AstraZeneca
Isabella Russell, Monash University - CCeMMP
Shane Wright, Karolinska Institute
William Lee, Domainex
Silke Kleinbölting, InSingulo
Daniel Benjamin, Immuto Scientific
Marcus Saarinen, Karolinska Institute
Niklas Larsson, AstraZeneca

Organised by

Arjan Snijder, AstraZeneca
Jens Carlsson, Uppsala University
Linda Johansson, Gothenburg University
Matija Rojnik, InSingulo

Attendees are encouraged to present their research in poster presentations. Abstract submission information will be available after you register for the event. Registration and poster abstract submission deadline is 10th April.

REGISTER HERE
insingulo.com/registration



SPONSORED BY



Location: AstraZeneca Gothenburg, Pepparedsleden 1, 431 50
Mölndal, Sweden

Date and time: Thursday, 18th April from 9.00 to 17.00

Conference Dinner: Wednesday 17th April at 19.00